Radiopharm RAD 101 Phase 2b Positive; 93% Met Endpoint; Raises $12.5M
Radiopharm Theranostics reported positive results from its Phase 2b clinical trial for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, early clinical signs for RAD 204 showed a RECIST-confirmed Partial Response in the first patient of the third cohort. Post-quarter, Radiopharm raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan, with $3 million already subscribed, bolstering its financial position despite a quarter-end cash balance of $4.1 million.
Key Highlights
- RAD 101 Phase 2b trial showed 93% of patients met primary endpoint.
- Company plans to initiate RAD 101 Phase 3 registrational trial in Q4 2026.
- RAD 204 Phase 1 showed first patient with -43% tumor shrinkage.
- Raised approximately $12.5 million through an institutional offer.
- Launched $6 million Share Purchase Plan, with $3 million already subscribed.
- Closing cash at quarter-end was $4.1 million.
- Net cash outflow from operating activities was $14.97 million.
Price Impact
More from RADX
Radiopharm Theranostics RAD101 Phase 3 Trial Set for 1Q27; RAD301 Data Positive
Radiopharm Theranostics Seeks Approval for $18.5M Capital Raise
Radiopharm Theranostics Reports Positive RAD 101 Phase 2b Results; Raises $12.5M